tiprankstipranks
Syndax Pharmaceuticals Restructures Leadership Team
Company Announcements

Syndax Pharmaceuticals Restructures Leadership Team

Story Highlights

Pick the best stocks and maximize your portfolio:

Syndax Pharmaceuticals ( (SNDX) ) has shared an update.

Syndax Pharmaceuticals has announced the elimination of the Chief Medical Officer position, resulting in Catherine Madigan, M.D. departing from the company. This organizational change may impact Syndax’s operational dynamics, signaling potential shifts in their strategic focus or cost management efforts.

More about Syndax Pharmaceuticals

Syndax Pharmaceuticals operates in the biotechnology industry, focusing on developing therapies for cancer treatment.

YTD Price Performance: -40.54%

Average Trading Volume: 1,647,199

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $1.1B

For a thorough assessment of SNDX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlySyndax announces additional positive data from AUGMENT-101 trial of Revuforj
TheFlyKura Oncology price target lowered to $18 from $22 at Scotiabank
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App